<DOC>
	<DOCNO>NCT01273402</DOCNO>
	<brief_summary>This study do select appropriate TF2 bsMAb dose suitable pretargeting 111In/90Y-labeled hapten-peptide ( IMP-288 ) . Eligible patient receive fix dose 90Y-IMP-288 4 day TF2 antibody injection . Two different dose level TF2 study first part . Once appropriate TF2 dose select base information learn first 2 dose level , patient enrol onto several different increase dose level 90Y-IMP-288 .</brief_summary>
	<brief_title>Study TF2 Carcinoembryonic Antigen ( CEA ) Antibody Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Male female patient , &gt; 18 year age . document histologic cytologic diagnosis metastatic ( Stage IV ) colorectal cancer . must least one confirm measurable tumor lesion ( confirmed tumor site one either biopsyproven evidence disease progressive growth radiographically observe ) . Patients must fail standard therapy standard therapy exists . Patients must Karnofsky performance status ≥ 70 % ( equivalent ECOG 01 ) expect survival ≥ 3 month . Patients previously receive chimeric , CDRgrafted ( humanize ) , human IgG eligible provide prestudy evaluation demonstrate significant antiantibody reactivity TF2 . Hematologic parameter : WBC count must ≥ 3000/mm3 , granulocytes 1500/mm3 , platelet ≥ 100,000/m3 . Nonhematologic parameter : Patients without liver metastasis must bilirubin ≤ 1.5 institutional upper limit normal ( IULN ) , whereas bilirubin patient know liver metastasis must &lt; 2.5times IULN . AST/ALT must &gt; 2.5 time IULN . At least 2 week beyond corticosteroid , except low dos ( i.e. , 20 mg/day prednisone equivalent ) treat nausea illness rheumatoid arthritis . Patients able understand give write informed consent . Informed consent must obtain prior baseline study enrollment purpose . Women pregnant lactating . Women childbearing potential fertile men inform potential risk procreation participate trial advise must use effective contraception period 3 month . Patients plasma CEA &gt; 1000 ng/mL lesion exceed 10 cm diameter . Patients severe anorexia gastrointestinalrelated symptomatology ( e.g. , nausea , vomit ) . Patients know HIV hepatitis B C. Patients active second primary malignancy time study entry , exception carcinoma situ cervix . Patients know metastatic disease central nervous system . Patients evidence bone marrow metastasis . Screening required patient suspicion metastasis . Patients ≥ 25 % bone marrow involvement exclude . Patients , opinion investigator , unable comply protocol requirement . Institutionalized subject ( e.g. , prison , psychiatric facility ) . Known history active coronary artery disease , unstable angina , myocardial infarction , congestive heart failure present within 6 month cardiac arrhythmia require antiarrhythmia therapy . Known autoimmune disease presence autoimmune phenomenon ( except rheumatoid arthritis require low dose maintenance corticosteroid ) ; infection require intravenous antibiotic use within 1 week . Known history active COPD , moderatetosevere respiratory illness present within 6 month . Patients diabetic and/or high blood pressure high risk develop latestage renal failure . While patient specifically exclude , physicianinvestigators must carefully discuss associate late risk patient . Patients must least 4 week beyond prior chemotherapy , surgery , radiotherapy index lesion , experimental therapy ( i.e. , drug , biologicals , procedure ) meet eligibility criterion . Patients receive treatment contain nitrosourea compound enrol least 6 week end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>TF2 ( Recombinant , humanize Tri-Fab bsMAb compose 2 humanized MN-14 anti-CEA Fab x one 679 anti-HSG Fab )</keyword>
	<keyword>IMP288 ( DOTA-di-HSG hapten-peptide 111In/90Y labeling )</keyword>
</DOC>